A randomized phase II study: sequencing topoisomerase inhibitors for extensive stage small cell lung cancer (SCLC): topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide.

Trial Profile

A randomized phase II study: sequencing topoisomerase inhibitors for extensive stage small cell lung cancer (SCLC): topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Irinotecan (Primary) ; Topotecan (Primary) ; Cisplatin; Etoposide; Etoposide; Filgrastim
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2012 Planned end date changed from 1 Jul 2005 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.
    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top